Is AMLX or CABA more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Amylyx Pharmaceuticals N/A -55.69% -50.73% Cabaletta Bio N/A -131.58% -96.46%

Is LKFT or CABA more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Cabaletta Bio N/A -131.58% -96.46%

Which has higher earnings & valuation, CABA or GHRS?

GH Research is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cabaletta Bio N/A N/A -$167.86M -$1.96 N/A GH Research N/A N/A -$48.26M -$0.92 N/A

Is CABA or GHRS more profitable?

GH Research's return on equity of -19.36% beat Cabaletta Bio's return on equity. Company Net Margins Return on Equity Return on Assets Cabaletta Bio N/A -131.58% -96.46% GH Research N/A -19.36% -18.73%

Cabaletta Bio (CABA) Competitors

$3.19 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.18 -0.01 (-0.38%)

As of 07/2/2026 07:59 PM Eastern

Compare

CABA vs. AMLX, NUVB, ATAI, LKFT, and GHRS

Should you buy Cabaletta Bio stock or one of its competitors? MarketBeat compares Cabaletta Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cabaletta Bio include Amylyx Pharmaceuticals (AMLX), Nuvation Bio (NUVB), Atai Beckley (ATAI), Lakefront Biotherapeutics American Depositary Shares (LKFT), and GH Research (GHRS). These companies are all part of the "pharmaceutical products" industry.

How does Cabaletta Bio compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Amylyx Pharmaceuticals has a beta of -0.2, indicating that its stock price is 120% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market.

Amylyx Pharmaceuticals presently has a consensus price target of $24.25, indicating a potential upside of 32.73%. Cabaletta Bio has a consensus price target of $15.50, indicating a potential upside of 385.89%. Given Cabaletta Bio's higher probable upside, analysts plainly believe Cabaletta Bio is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Amylyx Pharmaceuticals has higher revenue and earnings than Cabaletta Bio. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	23.25	-$144.74M	-$1.50	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Amylyx Pharmaceuticals' return on equity of -55.69% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Cabaletta Bio	N/A	-131.58%	-96.46%

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Amylyx Pharmaceuticals and 0 mentions for Cabaletta Bio. Amylyx Pharmaceuticals' average media sentiment score of 0.40 beat Cabaletta Bio's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amylyx Pharmaceuticals	Neutral
Cabaletta Bio	Neutral

Summary

Amylyx Pharmaceuticals beats Cabaletta Bio on 12 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to Nuvation Bio?

Cabaletta Bio (NASDAQ:CABA) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Cabaletta Bio has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Nuvation Bio	$62.90M	31.47	-$204.63M	-$0.43	N/A

Cabaletta Bio has a net margin of 0.00% compared to Nuvation Bio's net margin of -102.06%. Nuvation Bio's return on equity of -44.10% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Nuvation Bio	-102.06%	-44.10%	-23.80%

In the previous week, Nuvation Bio had 4 more articles in the media than Cabaletta Bio. MarketBeat recorded 4 mentions for Nuvation Bio and 0 mentions for Cabaletta Bio. Nuvation Bio's average media sentiment score of 0.63 beat Cabaletta Bio's score of 0.00 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Nuvation Bio	Positive

Cabaletta Bio has a beta of 3.26, suggesting that its share price is 226% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cabaletta Bio presently has a consensus price target of $15.50, indicating a potential upside of 385.89%. Nuvation Bio has a consensus price target of $12.50, indicating a potential upside of 119.88%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cabaletta Bio is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nuvation Bio	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Nuvation Bio beats Cabaletta Bio on 9 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to Atai Beckley?

Cabaletta Bio (NASDAQ:CABA) and Atai Beckley (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

28.4% of Atai Beckley shares are held by institutional investors. 6.4% of Cabaletta Bio shares are held by insiders. Comparatively, 26.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cabaletta Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Cabaletta Bio currently has a consensus target price of $15.50, indicating a potential upside of 385.89%. Atai Beckley has a consensus target price of $16.00, indicating a potential upside of 208.29%. Given Cabaletta Bio's higher possible upside, equities research analysts plainly believe Cabaletta Bio is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

In the previous week, Atai Beckley had 2 more articles in the media than Cabaletta Bio. MarketBeat recorded 2 mentions for Atai Beckley and 0 mentions for Cabaletta Bio. Atai Beckley's average media sentiment score of 0.89 beat Cabaletta Bio's score of 0.00 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Overall Sentiment
Cabaletta Bio	Neutral
Atai Beckley	Positive

Cabaletta Bio has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

Cabaletta Bio has higher earnings, but lower revenue than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
Atai Beckley	$4.09M	467.19	-$660.05M	-$2.23	N/A

Summary

Atai Beckley beats Cabaletta Bio on 10 of the 16 factors compared between the two stocks.

How does Cabaletta Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Cabaletta Bio (NASDAQ:CABA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $36.50, indicating a potential upside of 20.11%. Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 385.89%. Given Cabaletta Bio's stronger consensus rating and higher probable upside, analysts clearly believe Cabaletta Bio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.13
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.26, meaning that its stock price is 226% more volatile than the broader market.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Cabaletta Bio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.04B	1.92	$363.05M	-$1.41	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Cabaletta Bio	N/A	-131.58%	-96.46%

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Cabaletta Bio. MarketBeat recorded 3 mentions for Lakefront Biotherapeutics American Depositary Shares and 0 mentions for Cabaletta Bio. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.22 beat Cabaletta Bio's score of 0.00 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	Neutral
Cabaletta Bio	Neutral

Summary

Lakefront Biotherapeutics American Depositary Shares beats Cabaletta Bio on 9 of the 15 factors compared between the two stocks.

How does Cabaletta Bio compare to GH Research?

Cabaletta Bio (NASDAQ:CABA) and GH Research (NASDAQ:GHRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

56.9% of GH Research shares are owned by institutional investors. 6.4% of Cabaletta Bio shares are owned by company insiders. Comparatively, 41.6% of GH Research shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cabaletta Bio's average media sentiment score of 0.00 equaled GH Research'saverage media sentiment score.

Company	Overall Sentiment
Cabaletta Bio	Neutral
GH Research	Neutral

Cabaletta Bio currently has a consensus target price of $15.50, suggesting a potential upside of 385.89%. GH Research has a consensus target price of $40.38, suggesting a potential upside of 49.48%. Given Cabaletta Bio's higher possible upside, equities research analysts clearly believe Cabaletta Bio is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

GH Research's return on equity of -19.36% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-131.58%	-96.46%
GH Research	N/A	-19.36%	-18.73%

Cabaletta Bio has a beta of 3.26, indicating that its share price is 226% more volatile than the broader market. Comparatively, GH Research has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

GH Research is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A

Summary

GH Research beats Cabaletta Bio on 8 of the 11 factors compared between the two stocks.

Get Cabaletta Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CABA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CABA vs. The Competition

Export

Metric	Cabaletta Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$520.15M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.63	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.49
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	2.75	8.66	10.96	6.46
Net Income	-$167.86M	$23.81M	$3.57B	$337.01M
7 Day Performance	4.93%	3.39%	2.12%	1.69%
1 Month Performance	-1.85%	10.81%	5.25%	3.81%
1 Year Performance	98.63%	62.61%	33.29%	23.90%

Cabaletta Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CABA Cabaletta Bio	1.9801 of 5 stars	$3.19 flat	$15.50 +385.9%	+98.6%	$520.15M	N/A	N/A	50	Gap Down
AMLX Amylyx Pharmaceuticals	3.5095 of 5 stars	$18.70 +5.1%	$24.25 +29.7%	+190.0%	$1.98B	$87.37M	N/A	200
NUVB Nuvation Bio	4.0352 of 5 stars	$5.60 -1.0%	$12.50 +123.4%	+172.7%	$1.97B	$62.90M	N/A	60	Gap Down
ATAI Atai Beckley	3.5737 of 5 stars	$5.36 +1.3%	$16.00 +198.5%	+87.0%	$1.95B	$4.09M	N/A	80	News Coverage Gap Down
LKFT Lakefront Biotherapeutics American Depositary Shares	2.0343 of 5 stars	$29.67 +0.6%	$36.50 +23.0%	+5.4%	$1.94B	$1.26B	N/A	1,310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CABA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cabaletta Bio (CABA) Competitors

CABA vs. AMLX, NUVB, ATAI, LKFT, and GHRS

How does Cabaletta Bio compare to Amylyx Pharmaceuticals?

Summary

How does Cabaletta Bio compare to Nuvation Bio?

Summary

How does Cabaletta Bio compare to Atai Beckley?

Summary

How does Cabaletta Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Cabaletta Bio compare to GH Research?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cabaletta Bio (CABA) Competitors

CABA vs. AMLX, NUVB, ATAI, LKFT, and GHRS

How does Cabaletta Bio compare to Amylyx Pharmaceuticals?

Which has more risk and volatility, AMLX or CABA?

Do analysts recommend AMLX or CABA?

Which has stronger valuation & earnings, AMLX or CABA?

Is AMLX or CABA more profitable?

Do insiders & institutionals have more ownership in AMLX or CABA?

Does the media prefer AMLX or CABA?

Summary

How does Cabaletta Bio compare to Nuvation Bio?

Which has stronger valuation & earnings, CABA or NUVB?

Is CABA or NUVB more profitable?

Does the media refer more to CABA or NUVB?

Which has more volatility and risk, CABA or NUVB?

Do insiders and institutionals have more ownership in CABA or NUVB?

Do analysts recommend CABA or NUVB?

Summary

How does Cabaletta Bio compare to Atai Beckley?

Do insiders & institutionals have more ownership in CABA or ATAI?

Is CABA or ATAI more profitable?

Do analysts recommend CABA or ATAI?

Does the media prefer CABA or ATAI?

Which has more volatility & risk, CABA or ATAI?

Which has better earnings and valuation, CABA or ATAI?

Summary

How does Cabaletta Bio compare to Lakefront Biotherapeutics American Depositary Shares?

Do analysts prefer LKFT or CABA?

Which has more risk and volatility, LKFT or CABA?

Do insiders and institutionals have more ownership in LKFT or CABA?

Which has better valuation and earnings, LKFT or CABA?

Is LKFT or CABA more profitable?

Does the media prefer LKFT or CABA?

Summary

How does Cabaletta Bio compare to GH Research?

Do insiders & institutionals hold more shares of CABA or GHRS?

Does the media prefer CABA or GHRS?

Do analysts recommend CABA or GHRS?

Is CABA or GHRS more profitable?

Which has more risk and volatility, CABA or GHRS?

Which has higher earnings & valuation, CABA or GHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA vs. The Competition

Cabaletta Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools